

Luana Fianchi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5800296/publications.pdf>

Version: 2024-02-01

132
papers

4,882
citations

109321

35
h-index

98798

67
g-index

134
all docs

134
docs citations

134
times ranked

5716
citing authors

#	ARTICLE	IF	CITATIONS
1	The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. <i>Haematologica</i> , 2006, 91, 1068-75.	3.5	650
2	Fungal Infections in Recipients of Hematopoietic Stem Cell Transplants: Results of the SEIFEM B-2004 Study--Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. <i>Clinical Infectious Diseases</i> , 2007, 45, 1161-1170.	5.8	366
3	Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. <i>Haematologica</i> , 2010, 95, 644-650.	3.5	273
4	Mucormycosis in hematologic patients. <i>Haematologica</i> , 2004, 89, 207-14.	3.5	213
5	The risk of thrombosis in patients with acute leukemia: occurrence of thrombosis at diagnosis and during treatment. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 1985-1992.	3.8	206
6	Incidence and clinical impact of extended-spectrum-β-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by <i>Escherichia coli</i> in patients with hematological malignancies. <i>Journal of Infection</i> , 2009, 58, 299-307.	3.3	144
7	Comparison of Real-Time PCR, Conventional PCR, and Galactomannan Antigen Detection by Enzyme-Linked Immunosorbent Assay Using Bronchoalveolar Lavage Fluid Samples from Hematology Patients for Diagnosis of Invasive Pulmonary Aspergillosis. <i>Journal of Clinical Microbiology</i> , 2003, 41, 3922-3925.	3.9	134
8	<i>Pneumocystis carinii</i> pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centres. <i>British Journal of Haematology</i> , 2002, 117, 379-386.	2.5	123
9	Bloodstream infections caused by <i>Klebsiella pneumoniae</i> in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey. <i>American Journal of Hematology</i> , 2016, 91, 1076-1081.	4.1	115
10	Invasive Aspergillosis in Patients with Acute Leukemia: Update on Morbidity and Mortality--SEIFEM-C Report. <i>Clinical Infectious Diseases</i> , 2007, 44, 1524-1525.	5.8	102
11	Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias. <i>American Journal of Hematology</i> , 2015, 90, E80-5.	4.1	93
12	Incidence and susceptibility to therapy-related myeloid neoplasms. <i>Chemico-Biological Interactions</i> , 2010, 184, 39-45.	4.0	85
13	Factors associated with mortality in bacteremic patients with hematologic malignancies. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009, 64, 320-326.	1.8	82
14	Acute megakaryoblastic leukemia: experience of GIMEMA trials. <i>Leukemia</i> , 2002, 16, 1622-1626.	7.2	81
15	The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients. <i>Oncogene</i> , 2007, 26, 3679-3690.	5.9	79
16	Zygomycosis in Italy: A Survey of FIMUA-ECMM (Federazione Italiana Di Micopatologia Umana ed) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 322-329.	1.5	79
17	NK/T-cell lymphomas -nasal type-™: an Italian multicentric retrospective survey. <i>Annals of Oncology</i> , 2006, 17, 794-800.	1.2	69
18	Primary plasma cell leukemia: a retrospective multicenter study of 73 patients. <i>Annals of Oncology</i> , 2011, 22, 1628-1635.	1.2	65

#	ARTICLE	IF	CITATIONS
19	Chronic disseminated candidiasis in patients with hematologic malignancies. Clinical features and outcome of 29 episodes. <i>Haematologica</i> , 2002, 87, 535-41.	3.5	64
20	Why methylation is not a marker predictive of response to hypomethylating agents. <i>Haematologica</i> , 2014, 99, 613-619.	3.5	61
21	High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study. <i>Leukemia and Lymphoma</i> , 2013, 54, 658-661.	1.3	54
22	MTHFR polymorphisms influence on outcome and toxicity in acute lymphoblastic leukemia patients. <i>Leukemia Research</i> , 2007, 31, 1669-1674.	0.8	53
23	Therapy-related myeloid neoplasms. <i>Current Opinion in Oncology</i> , 2011, 23, 672-680.	2.4	49
24	Outcome of therapy-related myeloid neoplasms treated with azacitidine. <i>Journal of Hematology and Oncology</i> , 2012, 5, 44.	17.0	49
25	Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2021, 39, 1426-1436.	1.6	49
26	Current therapeutic approaches to fungal infections in immunocompromised hematological patients. <i>Blood Reviews</i> , 2010, 24, 51-61.	5.7	47
27	Feasibility of allogeneic stem-cell transplantation after azacitidine bridge in higher-risk myelodysplastic syndromes and low blast count acute myeloid leukemia: results of the BMT-AZA prospective study. <i>Annals of Oncology</i> , 2017, 28, 1547-1553.	1.2	46
28	Advanced mast cell disease: an Italian Hematological Multicenter experience. <i>International Journal of Hematology</i> , 2008, 88, 483-488.	1.6	44
29	Invasive aspergillosis in acute myeloid leukemia: Are we making progress in reducing mortality?. <i>Medical Mycology</i> , 2017, 55, 82-86.	0.7	43
30	Fungal CNS infections in patients with hematologic malignancy. <i>Expert Review of Anti-Infective Therapy</i> , 2005, 3, 775-785.	4.4	42
31	Impairment of PI3K/AKT and WNT/ β -catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes. <i>Experimental Hematology</i> , 2016, 44, 75-83.e4.	0.4	42
32	Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-Azacitidine. <i>Leukemia</i> , 2011, 25, 1910-1913.	7.2	40
33	The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 691-696.	2.3	40
34	Invasive fungal infections in patients with acute myeloid leukemia and in those submitted to allogeneic hemopoietic stem cell transplant: who is at highest risk?. <i>European Journal of Haematology</i> , 2008, 81, 242-243.	2.2	38
35	Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. <i>European Journal of Haematology</i> , 2013, 90, 345-348.	2.2	37
36	Invasive fungal infections in chronic lymphoproliferative disorders: a monocentric retrospective study. <i>Haematologica</i> , 2017, 102, e108-e111.	3.5	37

#	ARTICLE	IF	CITATIONS
37	Epigenetic changes in therapy-related MDS/AML. <i>Chemico-Biological Interactions</i> , 2010, 184, 46-49.	4.0	36
38	Scedosporiosis in patients with acute leukemia: a retrospective multicenter report. <i>Haematologica</i> , 2008, 93, 104-110.	3.5	34
39	Tumor lysis syndrome: review of pathogenesis, risk factors and management of a medical emergency. <i>Expert Review of Hematology</i> , 2016, 9, 197-208.	2.2	33
40	Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes. <i>Leukemia</i> , 2019, 33, 785-790.	7.2	33
41	Fanconi anemia gene variants in therapy-related myeloid neoplasms. <i>Blood Cancer Journal</i> , 2015, 5, e323-e323.	6.2	32
42	Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia. <i>European Journal of Haematology</i> , 2016, 96, 344-351.	2.2	31
43	Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes. <i>Cancer</i> , 2018, 124, 1251-1259.	4.1	31
44	Gemtuzumab ozogamicin, cytosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia. <i>Annals of Oncology</i> , 2008, 19, 128-134.	1.2	30
45	ZYGOMYCOSIS: Current approaches to management of patients with haematological malignancies. <i>British Journal of Haematology</i> , 2009, 146, 597-606.	2.5	29
46	RNA editing signature during myeloid leukemia cell differentiation. <i>Leukemia</i> , 2017, 31, 2824-2832.	7.2	29
47	Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms. <i>Blood Cells, Molecules, and Diseases</i> , 2010, 45, 181-185.	1.4	28
48	Impaired bactericidal and fungicidal activities of neutrophils in patients with myelodysplastic syndrome. <i>Leukemia Research</i> , 2012, 36, 331-333.	0.8	28
49	CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program. <i>Blood Cancer Journal</i> , 2020, 10, 96.	6.2	28
50	Rituximab chimeric anti-CD20 monoclonal antibody treatment for refractory hemolytic anemia in patients with lymphoproliferative disorders. <i>Haematologica</i> , 2003, 88, 223-5.	3.5	28
51	Cryptococcosis in patients with hematologic malignancies. A report from GIMEMA-infection. <i>Haematologica</i> , 2004, 89, 852-6.	3.5	27
52	Pulmonary fungal infection with yeasts and pneumocystis in patients with hematological malignancy. <i>Annals of Medicine</i> , 2005, 37, 259-269.	3.8	25
53	Granulocyte colony-stimulating factor enhances the in vitro cytotoxicity of gemtuzumab ozogamicin against acute myeloid leukemia cell lines and primary blast cells. <i>Experimental Hematology</i> , 2006, 34, 54-65.	0.4	25
54	Secondary acute myeloid leukaemia: results of conventional treatments. Experience of GIMEMA trials. <i>Annals of Oncology</i> , 2005, 16, 228-233.	1.2	24

#	ARTICLE	IF	CITATIONS
55	Combined Voriconazole Plus Caspofungin Therapy for the Treatment of Probable Geotrichum Pneumonia in a Leukemia Patient. <i>Infection</i> , 2008, 36, 65-67.	4.7	24
56	INCIDENCE OF ACUTE MYELOID LEUKEMIA AFTER BREAST CANCER. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011, 3, e2011069.	1.3	24
57	Severe infectious complications in a patient treated with rituximab for idiopathic thrombocytopenic purpura. <i>Annals of Hematology</i> , 2007, 86, 225-226.	1.8	23
58	Polymorphisms of detoxification and DNA repair enzymes in myelodysplastic syndromes. <i>Leukemia Research</i> , 2009, 33, 1068-1071.	0.8	23
59	Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases. <i>Leukemia</i> , 2013, 27, 982-985.	7.2	22
60	The <i>BCL2L1</i> Leu21Arg variant and risk of therapy-related myeloid neoplasms and de novo myelodysplastic syndromes. <i>Leukemia and Lymphoma</i> , 2014, 55, 1538-1543.	1.3	22
61	Clonal evolution in therapy-related neoplasms. <i>Oncotarget</i> , 2017, 8, 12031-12040.	1.8	22
62	Dose-Dependent Effect of Granulocyte Transfusions in Hematological Patients with Febrile Neutropenia. <i>PLoS ONE</i> , 2016, 11, e0159569.	2.5	21
63	ITACA: A new validated international erythropoietic stimulating agent response score that further refines the predictive power of previous scoring systems. <i>American Journal of Hematology</i> , 2017, 92, 1037-1046.	4.1	20
64	Epigenetic therapy of myelodysplastic syndromes and acute myeloid leukemia. <i>Current Opinion in Oncology</i> , 2015, 27, 532-539.	2.4	19
65	Breakthrough Zygomycosis and Voriconazole. <i>Journal of Infectious Diseases</i> , 2005, 192, 1496-1497.	4.0	18
66	All-trans Retinoic Acid in Association with Low Dose Cytosine Arabinoside in the Treatment of Acute Myeloid Leukemia in Elderly Patients. <i>American Journal of Therapeutics</i> , 2007, 14, 351-355.	0.9	18
67	Fungal Pneumonia Due to Molds in Patients with Hematological Malignancies. <i>Journal of Chemotherapy</i> , 2006, 18, 339-352.	1.5	17
68	SETBP1 mutations in 106 patients with therapy-related myeloid neoplasms. <i>Haematologica</i> , 2014, 99, e152-e153.	3.5	16
69	In vivo priming with granulocyte colony-stimulating factor possibly enhances the effect of gemtuzumab-ozogamicin in acute myeloid leukemia: results of a pilot study. <i>Haematologica</i> , 2004, 89, 634-6.	3.5	16
70	Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia. <i>Annals of Hematology</i> , 2018, 97, 1767-1774.	1.8	15
71	Atypical presentation of progressive multifocal leukoencephalopathy in a multiple myeloma patient after auto-SCT successfully treated with combination therapy. <i>Bone Marrow Transplantation</i> , 2010, 45, 1668-1670.	2.4	14
72	Role of flow cytometric immunophenotyping in prediction of <i>BCR/ABL1</i> gene rearrangement in adult B-cell acute lymphoblastic leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 468-476.	1.5	14

#	ARTICLE	IF	CITATIONS
73	The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index. <i>Leukemia</i> , 2020, 34, 2451-2459.	7.2	14
74	Common Genetic Polymorphisms within NF κ B-Related Genes and the Risk of Developing Invasive Aspergillosis. <i>Frontiers in Microbiology</i> , 2016, 7, 1243.	3.5	13
75	Treatment Strategies for Invasive Aspergillosis in Neutropenic Patients: Voriconazole or Liposomal Amphotericin-B?. <i>Journal of Chemotherapy</i> , 2011, 23, 5-8.	1.5	12
76	Therapy-related myeloid neoplasms: clinical perspectives. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 5909-5915.	2.0	12
77	Rapid response of nodular <scp>CD</scp>30â€positive mycosis fungoides to brentuximab vedotin. <i>British Journal of Haematology</i> , 2015, 168, 617-617.	2.5	9
78	Efficacy of combined surgery and antifungal therapies for the management of invasive zygomycoses in patients with haematological malignancies. <i>Mycoses</i> , 2010, 53, 89-92.	4.0	8
79	SIMILARITIES OF ELDERLY AND THERAPY-RELATED AML. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011, 3, e2011052.	1.3	8
80	Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine. <i>Leukemia and Lymphoma</i> , 2013, 54, 1786-1787.	1.3	8
81	Letter to the Editor. <i>Leukemia and Lymphoma</i> , 2003, 44, 1441-1443.	1.3	7
82	Primary plasma cell leukemia followed by testicular plasmacytoma. <i>International Journal of Hematology</i> , 2011, 93, 224-227.	1.6	7
83	Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a â€Gruppo Romano Mielodisplasie (GROM)â€multicenter study. <i>Annals of Hematology</i> , 2016, 95, 1059-1065.	1.8	7
84	Caspofungin for the treatment of candidaemia in patients with haematological malignancies. <i>Clinical Microbiology and Infection</i> , 2010, 16, 298-301.	6.0	6
85	Small lymphocytic lymphoma in a patient with Fabry disease. <i>Leukemia and Lymphoma</i> , 2013, 54, 184-185.	1.3	6
86	Pulmonary infections in patients with myelodysplastic syndromes receiving frontline azacytidine treatment. <i>Hematological Oncology</i> , 2020, 38, 189-196.	1.7	6
87	Impact of invasive aspergillosis occurring during first induction therapy on outcome of acute myeloid leukaemia (SEIFEMâ€12B study). <i>Mycoses</i> , 2020, 63, 1094-1100.	4.0	6
88	High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study. <i>Journal of Fungi (Basel)</i> Tj ETQq0 0 0 rgBT /Overlock 10 T650 137 Td		
89	Invasive Fungal Infection in Patients with Myelodysplastic Syndrome: A Report of Twelve Cases. <i>Leukemia and Lymphoma</i> , 2002, 43, 1613-1617.	1.3	5
90	Pulmonary aspergillosis in hematologic malignancies: lights and shadows. <i>Haematologica</i> , 2008, 93, 1611-1616.	3.5	5

#	ARTICLE	IF	CITATIONS
91	5-Azacytidine in chronic myelomonocytic leukemia: case report and review of literature. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2011, 3, e2011011.	1.3	5
92	Transcription factors implicated in late megakaryopoiesis as markers of outcome after azacitidine and allogeneic stem cell transplantation in myelodysplastic syndrome. <i>Leukemia Research</i> , 2019, 84, 106191.	0.8	5
93	Polymorphisms within the TNFSF4 and MAPKAPK2 Loci Influence the Risk of Developing Invasive Aspergillosis: A Two-Stage Case Control Study in the Context of the aspBIOmics Consortium. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021, 7, 4.	3.5	5
94	Methylenetetrahydrofolate reductase polymorphisms in myelodysplastic syndromes and therapy-related myeloid neoplasms. <i>Leukemia and Lymphoma</i> , 2014, 55, 2942-2944.	1.3	4
95	Mutational analysis of bone marrow mesenchymal stromal cells in myeloid malignancies. <i>Experimental Hematology</i> , 2014, 42, 731-733.	0.4	4
96	Immunophenotypic analysis in 119 patients with acute myeloid leukemia following a previous malignancy: a comparison with the immunophenotype of 231 de novo AML. <i>Haematologica</i> , 2003, 88, 225-7.	3.5	4
97	Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome after bupropion treatment for smoking cessation. <i>Blood Coagulation and Fibrinolysis</i> , 2003, 14, 77-78.	1.0	3
98	Second malignancy after treatment of adult acute myeloid leukemia: cohort study on adult patients enrolled in the GIMEMA trials. <i>Leukemia</i> , 2004, 18, 651-653.	7.2	3
99	Azacitidine in a patient with myelodysplastic syndrome: Impact of switching from a 5-day to the approved 7-day dosing schedule. <i>Leukemia Research</i> , 2012, 36, e15-e17.	0.8	3
100	A POPULATION-BASED STUDY ON MYELODYSPLASTIC SYNDROMES IN THE LAZIO REGION (ITALY), MEDICAL MISCODING AND 11-YEAR MORTALITY FOLLOW-UP: THE GRUPPO ROMANO-LAZIALE MIELODISPLASIE EXPERIENCE OF RETROSPECTIVE MULTICENTRIC REGISTRY. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 9, e2017046.	1.3	3
101	Bloodstream Infections Caused By Klebsiella Pneumoniae in Onco-Hematological Patients: Incidence and Clinical Impact of Carbapenem Resistance in a Multicentre Prospective Survey. <i>Blood</i> , 2015, 126, 3757-3757.	1.4	3
102	Real-life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile. <i>American Journal of Hematology</i> , 2014, 89, 565-565.	4.1	2
103	Allogeneic Transplant for Mycosis Fungoides in Patient with Wiskott-Aldrich Syndrome. <i>Journal of Clinical Immunology</i> , 2018, 38, 7-9.	3.8	2
104	Mastocytosis: One Word for Different Diseases. <i>Oncology and Therapy</i> , 2018, 6, 129-140.	2.6	2
105	In vitro effect of eltrombopag alone and in combination with azacitidine on megakaryopoiesis in patients with myelodysplastic syndrome. <i>Platelets</i> , 2021, 32, 378-382.	2.3	2
106	Preliminary Results from CPX-351 Italian Compassionate Use Program Show High Response Rate and Good Tolerability in Poor Prognosis AML Patients. <i>Blood</i> , 2019, 134, 1363-1363.	1.4	2
107	Feasibility of Azacitidine As Bridge to Allogeneic Stem Cell Transplantation in Patients with Higher-Risk MDS or Low-Blast Count AML: Results of the BMT-AZA Multicenter Prospective Study. <i>Blood</i> , 2015, 126, 66-66.	1.4	2
108	Filamentous Fungi Infection in Patients with Myelodysplastic Syndrome. A Report of Twelve Cases. <i>Leukemia and Lymphoma</i> , 2002, 43, 1421-1425.	1.3	1

#	ARTICLE	IF	CITATIONS
109	Treatment of primary plasma cell leukemia with high doses of cyclophosphamide, bortezomib, and dexamethasone followed by double autologous HSCT. <i>Annals of Hematology</i> , 2020, 99, 207-209.	1.8	1
110	WT1 evaluation in higher-risk myelodysplastic syndrome patients treated with azacitidine. <i>Leukemia and Lymphoma</i> , 2020, 61, 979-982.	1.3	1
111	Pretreatment Health-Related Quality of Life Profile According to the EORTC QLQ-C30 in Patients with Myelodysplastic Syndromes (MDS): Analysis on 443 Lower-Risk MDS Patients. <i>Blood</i> , 2018, 132, 2293-2293.	1.4	1
112	Risk of Infectious Complications in Patients with Chronic Lymphocytic Leukemia in the Era of BCR Inhibitors: A Retrospective Single Institution Experience. <i>Blood</i> , 2018, 132, 5552-5552.	1.4	1
113	Gentuzumab-Ozogamicin, Cytosine Arabinoside, G-CSF Combination in the Treatment of Elderly Poor Prognosis Acute Myeloid Leukemia. A Multicentric Study.. <i>Blood</i> , 2005, 106, 4604-4604.	1.4	1
114	Cost Description on a Cohort of 659 Patients with Adult MDS Included into the Italian Lazio Region Registry (the GROM-L). <i>Blood</i> , 2015, 126, 5237-5237.	1.4	1
115	Epidemiology of Fungal Infections in Hematological Malignancies in Italy: SEIFEM-2004 Study (Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne).. <i>Blood</i> , 2005, 106, 4556-4556.	1.4	1
116	Epidemiology of Fungemia in Hematological Malignancies: Preliminary Report of Seifem-2015 Survey. <i>Blood</i> , 2015, 126, 4887-4887.	1.4	1
117	CPX-351 Induction in Secondary Acute Myeloblastic Leukemia: Extended Follow up from the Italian Compassionate Use Program. <i>Blood</i> , 2021, 138, 1262-1262.	1.4	1
118	Feasibility of Allogeneic Stem Cell Transplantation After Azacitidine in Patients with High Risk Myelodysplastic Syndromes or Low-Blast Count Acute Myeloid Leukemias: the Experience of the BMT-AZA Multicenter Prospective Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S83-S84.	0.4	0
119	Aggressive Light Chain Myeloma Originating a Double Peak on Serum Electrophoresis: What's Underneath?. <i>Acta Haematologica</i> , 2020, 143, 91-92.	1.4	0
120	Acute lymphoblastic leukemia in elderly patients: clinical characteristics, treatment and outcome. <i>Aging Health</i> , 2006, 2, 123-133.	0.3	0
121	Systemic Mastocytosis. A GIMEMA Multicenter Survey.. <i>Blood</i> , 2006, 108, 4874-4874.	1.4	0
122	Gentuzumab-Ozogamicin, Cytosine Arabinoside, G-CSF Combination (G-AraMy) in the Treatment of Secondary Acute Myeloid Leukemia in Elderly Patients.. <i>Blood</i> , 2007, 110, 4377-4377.	1.4	0
123	Caspofungin for the Treatment of Candidemia in patients with Hematological Malignancies. <i>Blood</i> , 2008, 112, 4838-4838.	1.4	0
124	Therapy-Related Myeloid Neoplasms: Report Of The Italian Network On Secondary Leukemias. <i>Blood</i> , 2013, 122, 2659-2659.	1.4	0
125	Real-Life Efficacy Of Azacitidine In Myelodysplastic Syndromes According To IPSS Cytogenetic Profile. <i>Blood</i> , 2013, 122, 5229-5229.	1.4	0
126	Incidence of Infectious Complications in MDS/AML Patients Treated with Azacitidine By the Italian Cooperative Groups Gruppo Romano MDS (GROM) and Basilicata MDS Registry. <i>Blood</i> , 2014, 124, 3265-3265.	1.4	0

#	ARTICLE	IF	CITATIONS
127	Granulocyte Transfusions at Appropriate Doses Improve Survival in Hematological Patients with Febrile Neutropenia. <i>Blood</i> , 2015, 126, 3566-3566.	1.4	0
128	Age and Gender-Related Pretreatment Quality of Life Profiles in Patients with Higher-Risk Myelodysplastic Syndromes. Establishing Benchmark Data from an International Study. <i>Blood</i> , 2015, 126, 2099-2099.	1.4	0
129	Inclusion of Patient's Self-Reported Fatigue into a Standard Laboratory Risk Classification Enhances Survival Prediction in Patients with Advanced Myelodysplastic Syndromes. <i>Blood</i> , 2016, 128, 1242-1242.	1.4	0
130	Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical-Biological Entity?. <i>Blood</i> , 2018, 132, 5516-5516.	1.4	0
131	Pretreatment symptom prevalence in patients with myelodysplastic syndromes (MDS) across all disease risk categories: Analysis of 914 patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, e18220-e18220.	1.6	0
132	Accuracy of bone marrow histochemical TP53 expression compared to the detection of TP53 somatic mutations in patients with myelodysplastic syndromes harbouring a del5q cytogenetic abnormality. <i>American Journal of Blood Research</i> , 2021, 11, 417-426.	0.6	0